Bio-Techne (TECH) CEO awarded RSUs and options; insider sale disclosed
Rhea-AI Filing Summary
Kim Kelderman, CEO and Director of Bio-Techne Corp (TECH), reported multiple equity transactions dated 08/15/2025. The filing shows a grant/award of 8,543 restricted stock units and an acquisition of 35,354 restricted stock units and 70,708 performance restricted stock units (all reported as acquisitions at $0), plus an acquisition of 90,441 stock options exercisable at $53.60 with an 08/15/2035 expiration.
The report also discloses a sale of 4,305 shares of common stock at $53.60 and a prior acquisition of 8,543 shares (code M) resulting in 55,273 shares beneficially owned after the transactions. Numerous outstanding stock options and performance awards with varying exercise prices and vesting/expiration schedules are listed.
Positive
- Significant long-term alignment via time- and performance‑based restricted stock units and options awarded to the CEO
- Large option grant (90,441 options with exercise price $53.60, expiring 08/15/2035) that vests over multiple years
Negative
- Insider sale of 4,305 common shares at $53.60 reported on 08/15/2025
- Potential dilution from numerous outstanding options and performance awards that could convert into many additional shares over time
Insights
TL;DR: CEO received significant equity awards while executing a small open-market sale.
The filing documents substantial equity grants to the CEO and director positionholder, including restricted stock units and performance awards that vest subject to time and performance conditions, and a large grant of options exercisable through 2035. These awards align executive compensation with long-term shareholder outcomes because many awards are performance- or time‑vested. The disclosed 4,305-share sale at $53.60 is recorded as a disposition but is small relative to aggregate beneficial ownership and outstanding option positions shown in the filing.
TL;DR: Multiple option and RSU grants expand potential dilution; a modest sale reduces immediate share count.
The schedule of derivative securities shows several option tranches with exercise prices ranging from $47.60 to $120.46 and expirations from 2026 through 2035, plus sizeable performance- and time‑based RSU pools. If vested and exercised, these awards could increase diluted share count over time. The report lists 55,273 shares beneficially owned following the transactions and numerous unexercised options and RSUs totaling many tens of thousands of potential shares, which is relevant for modeling future dilution scenarios.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 8,543 | $0.00 | -- |
| Grant/Award | Performance Restricted Stock Units | 70,708 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 35,354 | $0.00 | -- |
| Grant/Award | Stock Options (Right to Buy) | 90,441 | $0.00 | -- |
| Exercise | Common Stock | 8,543 | $0.00 | -- |
| Tax Withholding | Common Stock | 4,305 | $53.60 | $231K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Fully exercisable. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
